Anixa Biosciences (NASDAQ:ANIX) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Anixa Biosciences (NASDAQ:ANIX) issued its earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.

Shares of NASDAQ:ANIX traded up $0.05 during midday trading on Friday, reaching $4.38. The company’s stock had a trading volume of 705 shares, compared to its average volume of 469,969. Anixa Biosciences has a fifty-two week low of $1.70 and a fifty-two week high of $8.09. The company has a market capitalization of $137.67 million, a P/E ratio of -3.83 and a beta of 1.41. The stock’s fifty day simple moving average is $4.32.

A number of brokerages have issued reports on ANIX. Zacks Investment Research cut Anixa Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 27th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Anixa Biosciences in a report on Friday, May 21st. Finally, Aegis reissued a “buy” rating on shares of Anixa Biosciences in a report on Monday, February 15th.

In other Anixa Biosciences news, Director Arnold M. Baskies bought 10,000 shares of the stock in a transaction dated Thursday, March 25th. The stock was bought at an average cost of $4.80 per share, for a total transaction of $48,000.00. Following the completion of the purchase, the director now owns 15,600 shares in the company, valued at approximately $74,880. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders bought 30,000 shares of company stock valued at $137,150. 19.80% of the stock is currently owned by corporate insiders.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.

Featured Story: Technical Analysis of Stocks, How Can It Help

Earnings History for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.